CTRI/2020/04/024915尚未招募2 期
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
Max Super Speciality Hospital A Unit of Devki Devi Foundation0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients admitted with RT-PCR confirmed COVID-19 illness.
- •2. Age > 18 years
- •3. Written informed consent
- •4. Has any of the two
- •a. PaO2/ FiO2 <300
- •b. Respiratory Rate > 24/min and SaO2 < 93% on room air
排除标准
- •1. Pregnant women
- •2. Breastfeeding women
- •3. Known hypersensitivity to blood products
- •4. Receipt of Pooled Immunoglobulin in last 30 days
- •6. Participating in any other clinical trial
- •7. Clinical status precluding infusion of blood products
研究者
相似试验
尚未招募
不适用
A Clinical Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.CTRI/2020/05/025346Government of TamilNadu
已完成
2 期
Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease.CTRI/2020/04/024775Indian Council Of Medical Research464
尚未招募
2 期
Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19 Cancer Patients.CTRI/2020/07/026514Tata Memorial Centre
尚未招募
2 期
Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19CTRI/2020/05/025337Tata Memorial Centre
进行中（未招募）
不适用
A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas - N/AEUCTR2005-000666-39-SEMediGene AG200